Navigating the Peptide jungle.

Berlin. On TikTok they promise eternal youth. In biohacker forums they are traded like hardware updates for the human body. On the World Anti-Doping Agency's prohibited list they sit prominently. And in specialized medical practices they are administered under strict protocol. Peptides, short chains of amino acids, are by far the most confusing chapter of the current longevity movement, and this spring it has only grown more confusing.

Anyone looking for a guide through this thicket quickly arrives at Dr. Dr. Dominik Duscher. An Austrian plastic surgeon and regenerative medicine researcher trained at the Medical University of Vienna, University College London, Harvard Medical School, and with a postdoctoral fellowship in stem cell biology at Stanford, Duscher serves as Medical Director of Recover Society. His newly released Peptide Guide reads like the opposite of what Instagram suggests: sober, dose-driven, full of stop criteria.

"Peptides are tools, not miracle drugs. They amplify what the body already does: repair, regulate, regenerate. They replace neither sleep nor movement nor nutrition."

Scientifically, peptides are small protein building blocks, shorter than a protein, longer than a single amino acid. They function as signaling molecules that the body itself produces, governing everything from immune defense to wound healing. The therapeutic logic: if you deliver these signals to the body in a targeted way, you can prompt its own repair machinery into action. Sounds simple. It is not.

Five domains, five promises

Duscher's manual sorts roughly two dozen of the most relevant peptides into five clinical fields.

First, longevity and mitochondria. Here, experimental candidates dominate, such as Epithalon, MOTS-c, and the senolytic FOXO4-DRI, designed to selectively eliminate senescent cells. "Highly experimental," Duscher emphasizes. "Burst protocol, six doses, no more than one to two cycles per year, always with informed consent."

Second, immunology. Thymosin alpha-1, a 28-amino-acid peptide that modulates T cell maturation, is the headliner here. It is used in several countries to treat chronic viral infections; in Western medicine, mostly off-label. Alongside it: KPV, an alpha-MSH fragment that calms inflammation in the gut mucosa, and the antimicrobial LL-37, with its notorious Herxheimer risk if introduced too quickly.

Third, recovery. This is where the celebrities of the scene live: BPC-157 and TB-500. Both are used in sports and rehabilitation for tendon, ligament, and muscle healing. Both have shown remarkable effects in animal models. Both have almost no robust human trials. "We use them in short cycles, four to six weeks, with clear functional outcome measurement. If the patient is not better after two weeks, we stop." Alongside them runs the growth hormone axis: CJC-1295 with or without DAC, combined with Ipamorelin, the classic off-label standard for stimulating the body's own GH secretion.

Fourth, body recomposition. Tesamorelin, a GHRH analog, is one of the few peptides with a real FDA approval, though only for HIV-associated lipodystrophy. Off-label, it is used to reduce visceral fat in patients with metabolic risk profiles. Alongside it sit IGF-1 LR3 for muscle growth, Follistatin as an experimental myostatin blocker, and AOD-9604 for lipolysis. All four appear on WADA's lists in one form or another.

Fifth, neurology and sexual medicine. Here, substances are emerging from the clinic. PT-141, a melanocortin agonist, is approved in the United States as Bremelanotide for Hypoactive Sexual Desire Disorder. Selank and Semax, intranasal nootropics in clinical use in Russia, are treated as research chemicals in the EU. Kisspeptin, a hypothalamic regulator of the sexual axis, remains experimental.

The regulatory reality: Washington reverses course

This is where the real slalom begins, and the lines are shifting noticeably right now. Until early 2026, the most popular peptides, BPC-157, TB-500, AOD-9604, CJC-1295, Ipamorelin, and a dozen more, sat on the FDA's Category 2 "Do Not Compound" interim list. United States compounding pharmacies were barred from producing them. Documented safety and quality concerns were the official rationale.

On February 27, 2026, US Health Secretary Robert F. Kennedy Jr. announced a reversal: roughly a dozen of the restricted compounds would return to Category 1. By April 23 the nominations were officially withdrawn and the peptides came off Category 2. On July 23 and 24 the FDA's Pharmacy Compounding Advisory Committee meets to formally vote on Category 1 reinstatement. In practice that means: licensed 503A pharmacies will once again be allowed to prepare many of these peptides on a valid physician's prescription.

This is explicitly not the same as FDA approval. Efficacy and safety trials remain absent, use stays off-label, the substances remain prescription-only compounded preparations. Kennedy's argument: the Category 2 listing produced precisely the gray market it was designed to suppress. Critics counter that the reclassification proceeds without new data, lending the patina of regulatory legitimacy to a poorly characterized class of substances. Europe is unaffected by the shift, and remains uneven.

In sport, the picture is clearer, and for professionals, harsher. The WADA prohibited list distinguishes several relevant categories. S2 covers peptide hormones and growth factors, meaning everything around the GH/IGF-1 axis: Tesamorelin, CJC, Ipamorelin, IGF-1 LR3. S4 covers hormonal and metabolic modulators, including Follistatin. S0, the most stringent category, covers all non-approved substances, which is to say precisely those compounds traded most heavily in the scene: BPC-157, TB-500, AOD-9604. "If you compete, you check GlobalDRO before every application," Duscher says. "Period." The FDA shift changes none of that.

There is also the quality question. The peptide gray market is large, opaque, and dangerous. Active ingredient concentrations fluctuate, contamination is documented, endotoxin loads are a real risk. Duscher works exclusively with pharmacy-grade preparations backed by a Certificate of Analysis, with batch tracking and a documented cold chain.

"That is the actual leverage of the US reform. If 503A pharmacies can produce again, supply migrates from Telegram channels into regulated cleanroom production. That is a safety upgrade and not an efficacy claim."

Indication, measurement, reversibility

What separates medical expertise from wellness vendors is governance. Every cycle begins with baseline lab work: complete blood count, CRP, metabolic panel, and depending on the axis, IGF-1, thyroid, hormone profiles. Every cycle begins with one to three clinical KPIs that the patient has to understand: waist circumference down three centimeters, PSQI improved by two points, IIEF-5 up four points. First check at week two, second at week four to six, then the verdict.

"If nothing measurably improves, we stop. If relevant side effects appear, we stop. If the goal is achieved, we stop."

Continuous use, he says, is the exception in his practice; the short, clearly defined cycle is the rule. "Cycle, don't continue" is one of the maxims that recurs throughout the manual. Duscher distrusts anecdote: his book lists hard scores for every indication, from the Pittsburgh Sleep Quality Index to the FSFI for female sexual function. "The subjective has to mirror the objective, otherwise we cannot attribute anything."

What patients should take away

Three messages, the physician offers at the close.

1. The foundation matters. Peptides only work when sleep, movement, nutrition and inflammatory load are in place. They modulate, they do not replace.
2. Setting matters. Anyone experimenting with peptides should do so in an environment where substance quality, dosing, monitoring, and stop criteria are governed. A loosened FDA rule does not turn a powder ordered on Telegram into a medicine.
3. Evidence is missing. The future of this class depends on studies that are urgently needed, at least for its most popular members. Washington's reclassification improves access; it does not replace evidence. Until those trials exist, every cycle counts as an individual therapeutic trial.

"The science behind most peptides is interesting. The hype around them is dangerous. Serious medicine lives precisely in the space between."Dr. Dr. Dominik Duscher, Medical Director, Recover Society